Overview

Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
In patients with schizophrenia, 'atypical' antipsychotics such as clozapine may be effective in the treatment of psychosis. In patients with borderline personality disorder (BPD), as far as the investigators know, no well designed controlled studies have been performed on the effect of one of the newer atypical antipsychotics on psychotic symptoms. It is of interest to investigate the benefit of quetiapine treatment in these types of patients. Quetiapine possibly gives less side-effects because of the expected lack of elevated prolactin levels, which is of importance in this patient group, overrepresented by young females. In this double blind, randomized, placebo controlled, 8 week, parallel group, multi-center study, quetiapine (in flexible doses between 200 mg/day and 600 mg/day) will be compared with the placebo.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Quetiapine Fumarate